Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder

International Clinical Psychopharmacology

Volumn 31, Issue 6, 2016, Pages 332-340

  Thase, Michael E ^a   Gommoll, Carl ^b   Chen, Changzheng ^b   Kramer, Kenneth ^b   Sambunaris, Angelo ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ALLERGAN INC   (United States)

^c Advanced Clinical Research   (United States)

Author keywords

antidepressant; apathy; depression; fatigue; serotonin and norepinephrine reuptake inhibitor

Indexed keywords

MILNACIPRAN; PLACEBO; ANTIDEPRESSANT AGENT; CYCLOPROPANE DERIVATIVE;

ADULT; ADULT DISEASE; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; FUNCTIONAL DISEASE; FUNCTIONAL STATUS ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOTIVATION AND ENERGY INVENTORY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHEEHAN DISABILITY SCALE; SINGLE BLIND PROCEDURE; ADMINISTRATION AND DOSAGE; CLINICAL TRIAL; CONVALESCENCE; DELAYED RELEASE FORMULATION; DRUG EFFECTS; MIDDLE AGED; MOTIVATION; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTIVATION; PSYCHIATRIC STATUS RATING SCALES; RECOVERY OF FUNCTION; TREATMENT OUTCOME;

EID: 84979664013     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000138     Document Type: Article

References (21)

1. APA (2010). Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. Arlignton, VA: American Psychiatric Association.
2. Auclair AL, Martel JC, Assié MB, Bardin L, Heusler P, Cussac D, et al. (2013). Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology 70:338-347.
3. Calabrese SR, Fava M, Garibaldi G, Grunze H, Krystal AD, Laughren T, et al. (2014). Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. J Affect Disord 168:439-451.
4. Demyttenaere K, de Fruyt J, Stahl SM (2005). The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol 8:93-105.
5. El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Blier P (2010). Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther 16:e1-e17.
6. Fehnel SE, Mcleod LD (2005). Psychometric evaulation of the motivation and energy inventory-short form (MEI-SF). Presented at the International Society for Quality of Life Research (ISOQOL) Annual Meeting; San Francisco, CA: 19-22 October 2005.
7. Fehnel SE, Bann CM, Hogue SL, Kwong WJ, Mahajan SS (2004). The development and psychometric evaluation of the motivation and energy inventory (MEI). Qual Life Res 13:1321-1336.
8. Hardeveld F, Spijker J, de Graaf R, Nolen WA, Beekman AT (2010). Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand 122:184-191.
9. Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, et al. (2009). Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 23:531-538.
10. Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava RK, Gee MD, et al. (2010a). Double-blind, placebo-controlled evaluation of extendedrelease bupropion in elderly patients with major depressive disorder. J Psychopharmacol 24:521-529.
11. Hewett K, Gee MD, Krishen A, Wunderlich HP, le Clus A, et al. (2010b). Doubleblind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 24:1209-1216.
12. Lam RW, Filteau MJ, Milev R (2011). Clinical effectiveness: the importance of psychosocial functioning outcomes. J Affect Disord 132 (Suppl 1):S9-S13.
13. McClintock SM, Husain MM, Wisniewski SR, Nierenberg AA, Stewart JW, et al. (2011). Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol 31:180-186.
14. McKnight PE, Kashdan TB (2009). The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev 29:243-259.
15. Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, et al. (2007). The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 21:461-471.
16. Pulcu E, Elliott R (2015). Neural origins of psychosocial functioning impairments in major depression. Lancet Psychiatry 2:835-843.
17. Rothschild AJ, Raskin J, Wang CN, Marangell LB, Fava M (2014). The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. Compr Psychiatry 55:1-10.
18. Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV (2014). A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol 34:47-56.
19. Soczynska JK, Ravindran LN, Styra R, McIntyre RS, Cyriac A, Manierka MS, Kennedy SH (2014). The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial. Psychiatry Res 220:245-250.
20. Stahl SM (2002). The psychopharmacology of energy and fatigue. J Clin Psychiatry 63:7-8.
21. Uher R, Perlis RH, Henigsberg N, Zobel A, Rietschel M, Mors O, et al. (2012). Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med 42:967-980.